var data={"title":"Neostigmine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Neostigmine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6643?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=neostigmine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Neostigmine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=neostigmine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Neostigmine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200742\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bloxiverz</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200743\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Prostigmin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200781\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Acetylcholinesterase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200746\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Neostigmine (Prostigmin) tablets have been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myasthenia gravis: Diagnosis:</b> <i>Canadian labeling:</i> <b>Note:</b> Pretreatment with atropine is recommended, and atropine should be available if a cholinergic reaction occurs. IM: 0.022 mg/kg as a single dose. If test is inconclusive, retesting can be done on a different day with a single dose of 0.031 mg/kg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myasthenia gravis: Treatment:</b> <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Initial dose: 15 mg 3 times daily. Usual dose: 150 mg in divided doses, administered over a 24-hour period; interval between doses should be adjusted per patient response with larger doses provided at times of most fatigue. Dosage range: 15 to 375 mg daily in divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV, SubQ: 0.5 to 2.5 mg; dosing based on individual patient response</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reversal of nondepolarizing neuromuscular blockade after surgery:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bloxiverz: IV: <b>Note:</b> An anticholinergic agent (atropine or glycopyrrolate) should be given intravenously prior to or in conjunction with neostigmine; in the presence of bradycardia, administer the anticholinergic prior to neostigmine. Peripheral nerve stimulation delivering train-of-four (TOF) stimulus must also be used to determine time of neostigmine initiation and need for additional doses. Prior to administration, there must be a twitch response to the first stimulus in the TOF of at least 10% of baseline.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Usual dose:</i> 0.03 to 0.07 mg/kg generally achieves a TOF twitch ratio of 90% within 10 to 20 minutes of administration; maximum total dose: 0.07 mg/kg or 5 mg (whichever is less)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dose selection guide: </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">The 0.03 mg/kg dose is recommended for reversal of NMBAs with shorter half-lives (eg, rocuronium); <b>or</b> when the first twitch response to the TOF stimulus is substantially &gt;10% of baseline or when a second twitch is present.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">The 0.07 mg/kg dose is recommended for NMBAs with longer half-lives (eg, vecuronium, pancuronium); <b>or</b> when the first twitch response is relatively weak (ie, not substantially &gt;10% of baseline); or rapid recovery is needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> IV: 0.5 to 2.5 mg; repeat as required. Only in exceptional cases should the total dose exceed 5 mg. <b>Note:</b> Administer with atropine 0.6 to 1.2 mg intravenously in a separate syringe several minutes before neostigmine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative bladder distention/urinary retention:</b> IM, SubQ: <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prevention:</i> 0.25 mg as soon as possible after operation; repeat every 4 to 6 hours for 2 to 3 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i> 0.5 to 1 mg; if urination does not occur within an hour, patient should be catheterized. After the bladder has emptied or patient has voided, doses may be repeated every 3 hours for 5 doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute colonic pseudo-obstruction (Ogilvie syndrome) (off-label use):</b> IV: 2 mg over 3 to 5 minutes (Ponec 1999). <b>Note:</b> Administration over 60 minutes may reduce the incidence of bradycardia; however, efficacy may be reduced (Abeyta 2001). Ensure atropine is available at the bedside to treat symptomatic neostigmine-induced bradycardia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200763\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=neostigmine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Neostigmine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Neostigmine (Prostigmin) tablets have been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myasthenia gravis:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Diagnosis:</i> <b>Note:</b> Pretreatment with atropine is recommended, and atropine should be available. IV fluids also recommended. Children &lt;2 years: IM: 0.04 mg/kg once; if results equivocal or negative, may be repeated once in 4 hours. Typical dose is 0.5 to 1.5 mg (Kliegman 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i> <b>Note:</b> Dosage requirements are variable; dosage should be individualized: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 0.3 to 2 mg/kg/day in divided doses (Silvestri 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV, SubQ: 0.01 to 0.04 mg/kg every 2 to 6 hours (Kliegman 2007; Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reversal of nondepolarizing neuromuscular-blocking agents (NMBAs) after surgery (Bloxiverz):</b> Infants, Children, and Adolescents: IV: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200747\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200748\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">There are no dosage adjustments provided in manufacturer's labeling. The manufacturer recommends close monitoring in patients with impaired renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">The following adjustments have been recommended (Aronoff 2007): Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl 10 to 50 mL/minute: Administer 50% of normal dose. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &lt;10 mL/minute: Administer 25% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hemodialysis: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peritoneal dialysis: No dosage adjustment necessary </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Continuous renal replacement therapy (CRRT): Administer 50% of normal dose </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20210378\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling; has not been studied.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200722\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as methylsulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg/mL (10 mL [DSC]); 1 mg/mL (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as methylsulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bloxiverz: 5 mg/10 mL (10 mL); 10 mg/10 mL (10 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/10 mL (10 mL); 10 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as methylsulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/5 mL (5 mL); 2 mg/2 mL (2 mL); 3 mg/3 mL (3 mL); 4 mg/4 mL (4 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200710\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28185877\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Neostigmine (Prostigmin) tablets have been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200725\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Tablets (neostigmine bromide): Prostigmin [Canadian product]: Muscarinic effects may be decreased when administered with food or milk. Consider giving larger portions of the daily dose around fatigue prone times (eg, mealtimes, afternoons).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injectable (neostigmine methylsulfate):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neostigmine Omega, Prostigmin [Canadian products]: Neostigmine Omega, Prostigmin [Canadian products]: May be administered IM, IV, or SubQ.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bloxiverz: Administer by slow IV injection over at least 1 minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acute colonic pseudo-obstruction (off-label use): Administer IV over 3 to 5 minutes (Ponec 1999). Administration over 60 minutes may reduce the incidence of bradycardia; however, efficacy may be reduced (Abeyta 2001).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200724\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>US labeling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reversal of nondepolarizing muscle relaxants:</b> Reversal of effects of nondepolarizing neuromuscular blocking agents after surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Canadian labeling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myasthenia gravis:</b> Symptomatic control of myasthenia gravis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Limitations of use: Other agents may be preferred for symptomatic treatment or acute exacerbations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postoperative bladder distention, Urinary retention:</b> Prevention and treatment of postoperative bladder distention and urinary retention after mechanical obstruction has been excluded.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reversal of nondepolarizing muscle relaxants:</b> Reversal of effects of nondepolarizing neuromuscular blocking agents after surgery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27254532\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute colonic pseudo-obstruction (Ogilvie&rsquo;s syndrome)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200789\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bloxiverz may be confused with Vazculep (phenylephrine injection) due to similar packaging</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Prostigmin may be confused with physostigmine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200716\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrioventricular block, cardiac arrhythmia (especially bradycardia), ECG changes (nonspecific), flushing, hypotension, nodal arrhythmia, syncope, tachycardia, thrombophlebitis (IV)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, drowsiness, dysarthria, headache, loss of consciousness, seizure, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, dysphagia, flatulence, increased peristalsis, nausea, salivation, stomach cramps, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary urgency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, fasciculations, laryngospasm, muscle cramps, muscle spasm, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Lacrimation, miosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, dyspnea, exacerbation of asthma, increased bronchial secretions, respiratory depression, respiratory paralysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200728\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to neostigmine or any component of the formulation; peritonitis or mechanical obstruction of the intestinal or urinary tract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to bromides (tablets only)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for cholinesterase inhibitors is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200714\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular effects: Bradycardia, hypotension, and dysrhythmias may occur, particularly with IV use; risk may be increased in patients with certain cardiovascular conditions (eg, coronary artery disease, cardiac arrhythmias, recent acute coronary syndrome). Risk may also be increased in patients with myasthenia gravis. When IV neostigmine is administered for the reversal of nondepolarizing neuromuscular-blocking agents, atropine or glycopyrrolate should be administered concurrently or prior to neostigmine to lessen the risk of bradycardia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cholinergic crisis: Overdosage may result in cholinergic crisis, characterized by extreme muscle weakness and potentially fatal respiratory paralysis. Cholinergic crisis should be distinguished from myasthenic crisis, which is also characterized by extreme muscle weakness, but would require radically different treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Symptoms of hypersensitivity have included anaphylaxis, angioedema, bradycardia, bronchospasm, erythema multiforme, facial swelling, flushing, generalized rash, hypotension, peripheral edema, pyrexia, and urticaria. Have atropine and epinephrine ready to treat hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular effects: Large doses of IV neostigmine administered for the reversal of nondepolarizing neuromuscular-blocking agents when neuromuscular blockade is minimal can result in neuromuscular dysfunction. Reduce dose if recovery from neuromuscular blockade is nearly complete.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Asthma: Use with caution in patients with asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with bradycardia, cardiac arrhythmias, coronary artery disease, or recent acute coronary syndrome. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Megacolon/GI dysfunction: Large oral doses should be avoided with megacolon or decreased GI motility. Neostigmine may accumulate; toxicity may result when motility is restored.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myasthenia gravis: Adequate facilities should be available for cardiopulmonary resuscitation when testing and adjusting dose for myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peptic ulcer disease: Use with caution in patients with peptic ulcer disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorder: Use with caution in patients with epilepsy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vagotonia: Use with caution in patients with vagotonia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: When used IV for the reversal of nondepolarizing muscle relaxants, pediatric and adult dosing is similar. However, recovery may be more rapid and risk of complications may be greater in infants and small children. Monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution and monitor for a longer period. Elderly patients experience slower spontaneous recovery from neuromuscular blocking agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299756\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200718\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9693&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers. <b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200719\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13855370\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies (doses used were below maximum expected human exposure based on BSA). Anticholinesterases have caused uterine irritability and induced premature labor with IV use in near-term pregnant women. When used as adjunct to analgesia in labor, adverse events to the fetus and mother are dose- and route-dependent (Habib 2006). Neostigmine may be used to treat myasthenia gravis in pregnant women; however, if an acetylcholinesterase inhibitor is needed during pregnancy, another agent may be preferred (Massey 2014; Norwood 2014; Silvestri 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617175\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if neostigmine is excreted into breast milk. The manufacturer recommends caution be used if administered to nursing women. Babies born to women with myasthenia gravis may have feeding difficulties due to transient myasthenia gravis of the newborn (Norwood 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21285938\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ECG, blood pressure, and heart rate especially with IV use; consult individual institutional policies and procedures</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acute colonic pseudo-obstruction (off-label use): Keep patient supine upon administration. Patient should receive continuous ECG monitoring with vital signs for 30 minutes and continuous clinical assessment for 15 to 30 minutes after administration (Saunders, 2005).   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200713\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits destruction of acetylcholine by acetylcholinesterase which facilitates transmission of impulses across myoneural junction; direct cholinomimetic effect on skeletal muscle and possible on autonomic ganglion cells and neurons of the CNS</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200727\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Peristaltic activity: Oral: 2 to 4 hours; Parenteral: 10 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: IM: 2.5 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Poor (~1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: IV: 0.12 to 1.4 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 15% to 25% to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Adults: 51 to 90 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Range: 24 to 113 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants 2 to 10 months: Mean: 39 &plusmn; 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 1 to 6 years: Mean: 48 &plusmn; 16 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults 29 to 48 years: 67 &plusmn; 8 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Anephric patients: 181 &plusmn; 54 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Renal transplant patients: 104.7 &plusmn; 64 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Adults: 42 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: 1 to 2 hours (Aquilonius 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (50% as unchanged drug; remainder as metabolites) (Aquilonius 1986)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323488\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bloxiverz Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/10 mL (10 mL): $73.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/10 mL (10 mL): $75.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Neostigmine Methylsulfate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/10 mL (10 mL): $75.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/10 mL (10 mL): $84.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Neostigmine Methylsulfate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/2 mL (2 mL): $25.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg/3 mL (3 mL): $37.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/4 mL (4 mL): $48.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (5 mL): $60.77</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200731\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bloxiverz (BM);</li>\n      <li>Episitgmin (SA);</li>\n      <li>Epistigmin (QA);</li>\n      <li>Fadastigmina (AR);</li>\n      <li>Flextig (BD);</li>\n      <li>Intrastigmina (IL, PT);</li>\n      <li>Metastigmin[inj.] (FI);</li>\n      <li>Miostin (RO);</li>\n      <li>Myostigmin (ET);</li>\n      <li>Neostigmin (HR, SE);</li>\n      <li>Neotalis (PH);</li>\n      <li>Normastigmin (AT);</li>\n      <li>Polstigminum (PL);</li>\n      <li>Prostig (BD, PH);</li>\n      <li>Prostigmin (AE, AT, BB, BF, BH, BJ, BM, BS, BZ, CH, CI, CY, CZ, DE, EC, EG, ET, GH, GM, GN, GY, ID, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PK, PR, PY, QA, SA, SC, SD, SG, SI, SL, SN, SR, SY, TH, TN, TT, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Prostigmin INJ (AU);</li>\n      <li>Prostigmina (IT);</li>\n      <li>Prostigmine (BE, BR, CL, CO, ES, FR, GR, LU, MX, PE, PT, UY, VN);</li>\n      <li>Prostigmin[inj.] (GB, HR, IE);</li>\n      <li>Setisin (MY);</li>\n      <li>Stigmin (KR);</li>\n      <li>Stigmosan (HU);</li>\n      <li>Stignal (BD);</li>\n      <li>Stigvita (LK);</li>\n      <li>Syntostigmin (BG);</li>\n      <li>Tilstigmin (IN, LK);</li>\n      <li>Vagostin (TW);</li>\n      <li>Versia (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11270887\"></a>Abeyta BJ, Albrecht RM, Schermer CR. Retrospective study of neostigmine for the treatment of acute colonic pseudo-obstruction. <i>Am Surg</i>. 2001;67(3):265-269.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/11270887/pubmed\" target=\"_blank\" id=\"11270887\">11270887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aquilonius SM, Hartviq P. Clinical pharmacokinetics of cholinesterase inhibitors. <i>Clin Pharmacokinet</i>. 1986;11(3):236-249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/3524957/pubmed\" target=\"_blank\" id=\"3524957\">3524957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bloxiverz (neostigmine) [prescribing information]. Chesterfield, MO: &Eacute;clat Pharmaceuticals; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habib AS and Gan TJ, &quot;Use of Neostigmine in the Management of Acute Postoperative Pain and Labour Pain: A Review,&quot; <i>CNS Drugs</i>, 2006, 20(10):821-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/16999453/pubmed\" target=\"_blank\" id=\"16999453\">16999453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Massey JM, De Jesus-Acosta C. Pregnancy and myasthenia gravis. <i>Continuum (Minneap Minn)</i>. 2014;20(1 Neurology of Pregnancy):115-127.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/24492814/pubmed\" target=\"_blank\" id=\"24492814\">24492814</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neostigmine Omega (neostigmine) [product monograph]. Montreal, Quebec, Canada: Omega Laboratories Limited; May 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Norwood F, Dhanjal M, Hill M, et al. Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. <i>J Neurol Neurosurg Psychiatry</i>. 2014;85(5):538-543.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/23757420/pubmed\" target=\"_blank\" id=\"23757420\">23757420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10703857\"></a>Paran H, Silverberg D, Mayo A, Shwartz I, Neufeld D, Freund U. Treatment of acute colonic pseudo-obstruction with neostigmine. <i>J Am Coll Surg</i>. 2000;190(3):315-318.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/10703857/pubmed\" target=\"_blank\" id=\"10703857\">10703857</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10403850\"></a>Ponec RJ, Saunders MD, and Kimmey MB, &quot;Neostigmine for the Treatment of Acute Colonic Pseudo-Obstruction,&quot; <i>N Engl J Med</i>, 1999, 341(3):137-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/10403850/pubmed\" target=\"_blank\" id=\"10403850\">10403850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prostigmin (neostigmine) [product monograph]. Montreal, Quebec, Canada: Valeant Canada; June 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saunders MD, Kimmey MB. Systematic review: acute colonic pseudo-obstruction. <i>Aliment Pharmacol Ther</i>. 2005;22(10):917-925.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/16268965/pubmed\" target=\"_blank\" id=\"16268965\">16268965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silvestri NJ, Wolfe GI. Myasthenia gravis. <i>Semin Neurol</i>. 2012;32(3):215-226.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/23117946/pubmed\" target=\"_blank\" id=\"23117946\">23117946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10826417\"></a>Trevisani GT, Hyman NH, Church JM. Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction. <i>Dis Colon Rectum</i>. 2000;43(5):599-603.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/10826417/pubmed\" target=\"_blank\" id=\"10826417\">10826417</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9693 Version 175.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F200742\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F200743\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F200781\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F200746\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F200763\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F200747\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F200748\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20210378\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F200722\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F200710\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F28185877\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F200725\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F200724\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F27254532\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F200789\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F200716\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F200728\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F200714\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299756\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F200718\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F200719\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13855370\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20617175\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F21285938\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F200713\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F200727\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323488\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F200731\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9693|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=neostigmine-patient-drug-information\" class=\"drug drug_patient\">Neostigmine: Patient drug information</a></li><li><a href=\"topic.htm?path=neostigmine-pediatric-drug-information\" class=\"drug drug_pediatric\">Neostigmine: Pediatric drug information</a></li></ul></div></div>","javascript":null}